Spyros Papapetropoulos

CIK: 0001832694

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

NEUP

Neuphoria Therapeutics Inc.

DirectorOfficer

LPCN

Lipocine Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

NEUP
Neuphoria Therapeutics Inc.
Aug 27, 2025
Award(A)
Employee Stock Option (Right-to- Buy)
Direct
34.6K shares at avg. $8.27-
LPCN
Lipocine Inc.
Jun 4, 2025
Award(A)
Stock Option (Right to Buy)
Direct
1.8K shares at avg. $3.20-
NEUP
Neuphoria Therapeutics Inc.
Apr 16, 2025
Award(A)
Employee Stock Option (Right-to-Buy)
Direct
27K shares at avg. $5.16-
NEUP
Neuphoria Therapeutics Inc.
Apr 16, 2025
Award(A)
Employee Stock Option (Right-to-Buy)
Direct
270K shares at avg. $5.16-

		Type	Shares	Price		Ownership
Aug 27, 2025	NEUP Neuphoria Therapeutics Inc.	Award(A) Employee Stock Option (Right-to- Buy)	34,559	$8.27	-	Direct
Jun 4, 2025	LPCN Lipocine Inc.	Award(A) Stock Option (Right to Buy)	1,764	$3.20	-	Direct
Apr 16, 2025	NEUP Neuphoria Therapeutics Inc.	Award(A) Employee Stock Option (Right-to-Buy)	27,000	$5.16	-	Direct
Apr 16, 2025	NEUP Neuphoria Therapeutics Inc.	Award(A) Employee Stock Option (Right-to-Buy)	270,000	$5.16	-	Direct

1-4 of 4 transactions

About Papapetropoulos Spyros

Papapetropoulos Spyros (SEC CIK 0001832694) files insider reports with the SEC as President and CEO of Neuphoria Therapeutics Inc. (NEUP) and Director of Lipocine Inc. (LPCN).

Signal8 holds 4 ownership filings by Papapetropoulos Spyros, all Form 4s, filed between Apr 18, 2025 and Sep 2, 2025. Those filings report 4 transactions, from Apr 16, 2025 to Aug 27, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Papapetropoulos Spyros's filings is in BURLINGTON, MA.

Recent filings by Papapetropoulos Spyros

Aug 27, 2025: Grant or award of NEUP derivative securities (Form 4, code A).
Jun 4, 2025: Grant or award of LPCN derivative securities (Form 4, code A).
Apr 16, 2025: Grants or awards of NEUP derivative securities (2 lines, Form 4, code A).

Other insiders filing for Neuphoria Therapeutics Inc. (NEUP)

How to read Form 4 transaction codes